Diagnosis of bone tumor currently relies on imaging and biopsy, and hence, the need to find less invasive ways for its accurate detection. More recently, numerous promising deoxyribonucleic acid (DNA) and protein biomarkers with significant prognostic, diagnostic and/or predictive abilities for various types of bone tumors have been identified from genomics and proteomics studies. This article reviewed the putative biomarkers for the more common types of bone tumors (that is, osteosarcoma, Ewing sarcoma, chondrosarcoma [malignant] and giant cell tumor [benign]) that were unveiled from the studies. The benefits and drawbacks of these biomarkers, as well as the technology platforms involved in the research, were also discussed. Challenges faced in the biomarker discovery studies and the problems in their translation from the bench to the clinical settings were also addressed.
confirmation of malignancy as well as to decide on whether surgery is required for the bone tumor patients (1) . If it was, the surgeon may suggest different types of surgery depending on the size and location of the tumor such as resection (removal parts or the bone affected), curettage (scraping out the tumor with out removal of the bone; usually used for benign tumor) and limb salvage surgery (removal of the cancer but still leaving some part of the limb for endo prosthesis). If the latter is not possible, amputation may be needed, which will definitely affect the normal function of the limb and, subsequently, the quality of life of the patient.
Currently, there are no specific mark ers that can be used to diagnose tumors of the bone. Biomarkers for early identi fication of the disease are greatly needed to reduce the mortality and increase limb salvage strategies (2) . Early de tection of either recurrent or metastatic disease can also prompt initial decision and action to treat the tumor, which may improve patient prognosis (3). Robbins and Kumar (4) had suggested that the elevated level of serum alkaline phosphatase released through osteoblas tic activity in the tumor may be used nerves or blood vessels. Rhabdomyo sarcomas, neurofibrosarcoma and an giosarcomas are a few examples of soft tissue sarcomas, whereas lipoblastoma and neurofibroma are benign soft tissue tumors.
Compared to most other tumors, a bone tumor can manifest pain early and is usually accompanied by local swell ing, fever and spontaneous fracture. Plain radiographs can be used to detect bone tumor in the initial diagnosis and also suggest the aggressiveness of the tumor. This step is usually followed by staging studies that can be carried out using various methods, including bone scintigraphy, computed tomography scan, positron emission tomography scan or magnetic resonance imaging. However, biopsy must be performed for
InTrODUCTIOn
The classification of bone tumor lies in the basis of the cell type from which the tumor originates. Aside from the bone, a neoplastic growth in bone tumors may also originate from the surrounding soft tissues, muscles and ligaments. Benign bone tumors, which are more common than malignant tumors, include osteo chondroma (derived from cartilage tumor), giant cell tumor (GCT), osteoid osteoma and osteoblastoma. The most commonly diagnosed malignant bone tumors, or often termed "sarcomas," are osteosarcoma (derived from osteo blastic cells), Ewing sarcoma (derived from round cell from bone marrow) and chondrosarcoma (derived from cartilage tumor). Some tumors may also develop from the soft tissues such as fat, muscle, biomarkers for bone Tumors: Discovery from Genomics and Proteomics Studies and Their Challenges biomarkers can usually be achieved using several approaches, including DNA sequencing, RNA expression and microRNA (miRNA) profiling, as well as epigenetic studies (14) .
DNA sequencing is the most common approach used to identify genetic muta tions in candidate genes, and it is also an important method in analyzing chromo somal rearrangement (that is, deletion, duplication, inversion and translocation of the chromosomes). The discovery of these genetic biomarkers usually starts with sequencing of exome (that is, the coding region of the human genome formed by exons) and/or whole genome sequencing. This step is usually followed by the validation phase, typically by mi crofluidic Sanger sequencing technology. Today, Sanger sequencing technology has been supplanted by nextgeneration sequencing methods, which can be used for a larger scale and automated genome analyses and also suitable for cross platform validation at a much lower cost (15) .
The discovery of epigenetic biomark ers stems from the ability of the DNA to undergo epigenetic modifications to the genome without any changes to the primary DNA sequence (16, 17) . Epi genetic alterations that are believed to be the causal events in cancers include DNA methylation, histone modification (methylation and acetylation), chromatin remodeling and regulation of noncoding RNAs (17, 18) . DNA methylation is the most extensively investigated as an epi genetic biomarker. In his review, Bock had outlined a systematic approach in the discovery of an epigenetic biomarker (18) . A candidate differentially meth ylated region (DMR) is often mapped using bisulfite sequencing with the aid of computational tools, which is con sidered as a gold standard method in validating DNA methylation profiling (18, 19) . The candidate DMRs are then tested using mediumscale customizable methods such as microarrays or hybrid selection sequencing. The selected top candidate DMR region-related genes are validated in large independent cohorts Biomarkers should ideally possess certain characteristics to make them clinically valuable. These characteristics include being easily measured, reliable and detectable using a cost effective assay without loss of analytical sensitiv ity or specificity (9) . Until 2013, Fuzery and coworkers listed 23 protein cancer biomarkers that had been approved by the U.S. Food and Drug Administration (FDA), the majority of which are for breast cancer (10) . The other biomarkers are for testicular, pancreatic, ovarian, colorectal, thyroid, prostate and bladder cancers. Although a lot of research has been carried out to identify biomarkers for bone tumors (Tables 1-4) , none of the proposed candidate has so far been approved by FDA for clinical settings.
Serum or plasma from blood and urine are the most frequently used sam ples in biomarker research because they are the easiest to sample from patients, and the method to obtain them is con sidered less invasive compared with tissue biopsy. These samples are well known to reflect various physiological and pathological states of the human body. There had been many biomarker studies that used tissue samples. How ever, these are not suitable for screening or early detection of diseases because the tissues usually came from patients who already had symptoms of the tumor (11) .
DISCOVErY STraTEGIES
Diagnostic, prognostic and predictive bio markers are most sought after in cancer research due to the urgent need in achieving a better clinical outcome for the patients (12) . Presently, genomics and proteomics technologies are the two most widely used approaches in biomarker discovery strategies.
Genomics Technologies
The word "genomics" was first coined by Thomas Huston Roderick, a geneticist at The Jackson Laboratory, Bar Harbor, Maine, in 1986. The term can be defined as the study of an organism's entire genome (13) . Discovery of genomics as an indicator. However, the enzyme was previously reported to be high in patients with diseases of the liver, thus making it unsuitable for use as a bone tumor marker (5, 6) . Furthermore, this marker may be more useful for monitor ing progression of bone tumor but not as its diagnostic marker.
A biological marker (biomarker) is a characteristic that is objectively mea sured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacologic responses to a therapeutic intervention (7) . It can be proteins, deoxyribonucleic acid (DNA), ribonucleic acid (RNA) or even metab olites. Biomarkers can be grouped into four main categories depending on their intended applications. First is a diagnos tic biomarker, which can be used as a tool in identifying diseases or abnormal con ditions in patients. On the other hand, a prognostic biomarker is an indicator that can predict tumor behavior and act as a marker of disease prognosis. The third type of biomarker is one that can be used in staging the disease, for example, in cancer. And finally, predictive biomark ers can be used to predict and monitor the clinical response after a treatment (7) .
Biomarkers can also be classified ac cording to their sources and functions, as explained by Baron in 2012 (8) . The first group is carcinogenesis biomarkers, which are products of the neoplastic process directly produced by the tumor itself (for example, mutated or hyper methylated DNA). The second group is response biomarkers, which are gen erated when the body responds to the presence of cancer (for example, antibod ies, protein degradation products and acutephase reactants). The third group is released biomarkers, which include physiological molecules that are released in abnormal amounts after anatomical or metabolic disruptions of carcinogenesis (for example, blood in the stool or pros tatespecific antigen in serum). Lastly, risk biomarkers, which consist of mo lecular markers associated with or sup porting the carcinogenesis (for example, increased hormone levels). (25) (26) (27) (28) .
The complexity of a sample such as serum also makes the gelbased pro teomics analysis a daunting task. To overcome these limitations, other pro teomics alternatives can be used, such as surfaceenhanced laser desorption/ ionization timeofflight mass spec trometry (SELDITOF MS) or a combi nation of liquid chromatography (LC) and MS. These techniques can analyze and finally utilization of annotated data bases to identify the proteins. Compared to genomics approaches, proteomics offers wider avenues for research. This result is because the genome of an organ ism is almost fixed, whereas proteome is always changing with time and from cell tocell, besides frequently being subjected to posttranslational modifications.
The most common techniques used to separate and isolate proteins are one and twodimensional gel electrophore ses (1DE and 2DE). In 1DE, pro teins are separated based on their molecu lar mass, and it can be used to sepa rate proteins with molecular mass of ~10-250 kDa. However, it has a limited resolving power, especially for more complex mixtures such as neat serum and crude cell lysate. Instead, 2DE can be used, since it can separate the proteins according to their net charge in the first dimension and to their mo lecular mass in the second. This step provides a much better resolution for complex mixtures compared with 1DE. The separation according to these two properties enables this method to also resolve proteins that had undergone posttranslational modifications (23, 24) . 2DE has also been modified to generate its variant, two dimensional difference gel electrophoresis (2DDIGE), where different protein samples can be re solved simultaneously in a single gel. Each protein sample is labeled with before entering the assay development and clinical trial phase.
In the case of expression biomarkers, which are derived from genes or RNA expression studies, genomics microarray is most frequently used because it is a powerful platform that can simultaneously measure the expression levels of thou sands of genes. Coupled with hierarchical clustering algorithms, the data analysis that leads to classification of the gene expression can suggest candidate biomark ers that have diagnostic, prognostic or predictive values. To validate the microar ray data, quantitative reverse transcription polymerase chain reaction (qRTPCR) is the most common method used and is considered the "gold standard" protocol in biomarker research (20) .
Proteomics Technologies
The term "proteome" was first coined by Marc Wilkins (21) and refers to the total protein complement of a genome. The term "proteomics" refers to the anal ysis of the protein complement of the ge nome (22) . In cancer research, proteomics has been widely applied in profiling the expression of proteins in cancer patients using various types of samples, includ ing blood (serum and plasma), urine, ce rebrospinal fluid, tear, saliva and tissues.
A typical proteomics experiment usu ally involves separation and isolation of proteins from a sample, acquisition of their structures and their characterization, is calculated on the basis of the differ ences between the areas of the XICs of the two ions with the same mass (46) . The labeling of these ions with isotopes can provide a more accurate result, but the cost involved is much higher than the labelfree method, and complex sam ple processing for this method can lead to sample loss. If one has already had the targeted molecules through the discovery phase, selective ion monitoring techniques can be applied for absolute quantitative measurements. Selection of appropriate and unique parent/product ion pairs for the analytes of interest using a powerful triple quadrupole mass spectrometer is known as single reaction monitoring (SRM) or multiple reaction monitoring (MRM), depending on the number of target ions screened (44, 47) . This nonscanning technique, unlike the shot gun approach, is highly selective and sensitive, which allows the researcher to direct the instrument to specifically monitor and do absolute quantification of target peptides or proteins of interest, even of low abundance, in a complicated matrix (44, 48) . MRM, which offers a rapid and specific quantification assay without the use of any antibodies, has a huge potential to be used as a biomarker validation tool (48) . It has been used to successfully quantify 45 proteins in the human plasma, which includes 31 puta tive bio markers for cardiovascular dis eases (49) . In a more recent study, Sung et al. (50) developed a highthroughput MRM assay to quantify and differentiate different iso forms of serum amyloid A (SAA), a putative protein biomarker for patients with lung cancer.
bIOMarKEr FOr bOnE TUMOrS FrOM GEnOMICS anD PrOTEOMICS STUDIES
Today, a large number of candidate biomarkers for bone tumors have been proposed via various genomics and proteomics studies. Biomarkers for os teosarcoma, being the most common type of bone tumor, are the most ex tensively sought after by researchers.
technique with high sensitivity and high specificity. The use of LCMS allows for the "shotgun proteomics" approach, a term used when an entire protein sam ple is subjected to proteolytic digestion yielding a highly complex mixture of peptides. The recovered peptides are subjected to the LC system, and in a typi cal reversephase singledimensional LC, the separation of the peptides in an LC column is based on hydrophobicity. The resulted elution is ionized before mass determination using MS. In the case of tandem MS (LCMS/MS), the recovered peaks are further fragmented and ana lyzed by a second MS. The LCMS itself is incapable of determining the amounts of proteins present in the sample. How ever, an approach using Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) can be used to comparatively quantify the proteins. This chemical labeling method incorporates stable isotopes into an amine tagging reagent before identification of the proteins using MS (43) . Currently, there are two sets of aminereactive isobaric tags available in the market, the 4plex and 8plex, which allow the labeling of from four and up to eight samples simultaneously. The tags are used to derivatize peptides at the Nterminus and the lysine side chains, therefore labeling all the peptides in a di gest mixture (43) . Upon fragmentation in the second MS (MS/MS), these tags will give rise to unique reporter ions (m/z) that can be used to quantify the respec tive samples.
Highthroughput relative protein quantification and identification can also be done using isotopic labeling of proteins or peptides and by means of labelfree quantification of derived mass spectra. In the labelfree LCMS method, the amount of peptides can be determined using the ion signal in tensities in the sample, where the data are collected in full MS scan mode to reconstruct the elution profile of the ions, thus producing the extracted ion chromatogram (XIC) (44, 45) . The abun dance of the analyte can be determined relatively between two samples, which complex mixtures with a simpler work flow and enables a greater number of samples to be analyzed. In addition, enrichment steps can also be performed to samples, to enable a study of a less complex subproteome. For (29) (30) (31) (32) .
Profiles obtained from lowmolecular weight serum protein analysis using SELDITOF MS has been suggested to reflect the pathological state of organs and aid in the early detection of cancer (33) (34) (35) . SELDITOF MS, first intro duced in 1993 by Hutchens and Yip (36) , is most valuable in profiling of low molecularweight peptides (<20 kDa), which cannot be achieved by LCMS and 2DE (37) . This novel approach combines both retention and MSbased methods on a relatively simple principle. Because of the unique surface chemistries of the chips, the system can be exploited to cater the use of different types of sam ples such as serum, plasma, urine and cell lysates. This platform has been suc cessfully used to profile serum proteins and has been used in the discovery of potential candidates of biomarker or proteomics patterns for lung cancer (38) , renal cancer (39), endometrial cancer (40) and gastric cancer (41) . However, it is incapable of directly carrying out the sequencebased identification of the discovered discriminatory peaks (42) . Identification of the resolved peaks must be performed using other proteomics work flow, for example, purification of the proteins of interest through chroma tography or gel electrophoresis, followed by MS analysis (39, 40) .
LCMS involves physical separation and mass analysis of peptides, making it a very powerful analytical chemistry compared with those with benign bone tumor. SAA, which is normally present at low levels in sera of healthy subjects, is secreted in response to inflammation and it is thought to be involved in tum origenesis (74) . In 2009, Folio et al. (66) showed that crystallin α/β (CRYAB) and ezrin (EZR) were significantly higher in osteosarcoma tissues compared with normal bone tissues, particularly in ad vanced stages of the disease. CRYAB protein has antiapoptotic functions, suggesting its involvement in the carcino genesis of osteosarcoma, whereas EZR is a membranecytoskeleton linker protein that is involved in the growth and metas tasis of various types of tumors (66) .
Other potential biomarkers for osteo sarcoma uncovered by proteomics studies include cytochrome C1 (CYC1), zinc finger protein 133 (ZNF133), tubulinα1c (TUBA1C), protein NDRG1 and gelsolin (67, 68, 70, 72) . CYC1 is a hemecontaining subunit of the cytochrome bc1 complex and is mainly known as an important participant in mitochondrial adenosine 5′triphosphate (ATP) synthesis (72, 75) . However, the relationship between this protein and tumorigenesis is relatively unknown. TUBA1C, a major cytoskeletal protein, was suggested as a key protein involved in metastasis and progression of osteosarcoma and therefore might be valuable as a prognostic indicator (70). Li et al. (70) also demonstrated the up regulation of ZNF133, a transcriptional repressor, in osteosarcoma tissues, but the exact function of this protein is still unknown (70) . Another potential diag nostic biomarker discovered by Hua et al. (67) is NDRG1, a protein that was found to be significantly upregulated in human osteosarcoma cell line and tissues. The specific biological function of NDRG1 is unknown, but there were reports that suggested it as a potential tumor suppres sor protein (76) . In a separate study by Jin et al. (68) , downregulation of another putative tumor suppressor, gelsolin, was reported in osteosarcoma. Gelsolin is involved in various biological functions such as apoptosis stimulator, cell motility, inflammation and wound healing (68) . the incidence of osteosarcoma and fluo ride exposure in drinking water during childhood (57) . However, their finding is only consistent among male subjects.
A vast number of biomarker studies of osteosarcoma had proposed a series of miRNA fingerprints and multigene clas sifiers as signatures ( Table 1) that may be used to reflect its pathogenesis and response to chemotherapy in patients (58-61), although singlegene miRNA biomarkers such as C7orf24, miR21, miRNA214 and a gene that codes for te nascinC protein had also been suggested (51, (62) (63) (64) . The upregulation of the C7orf24 gene, which was observed in human osteosarcoma cell lines and pri mary tumor samples, was suggested to be involved in cell adhesion and protein transport, and the knockdown of this gene apparently inhibited the growth of the cell lines (62) . Upregulation of miRNA214 has been found to correlate with aggressive clinicopathological fea tures and poor prognosis in pediatric osteosarcoma (63) , whereas higher miR 21 expression in the serum, which af fects the tumor behavior by modulating the cell growth, cell cycle progression, metastasis process and chemosensitivity of the tumor cells, appeared to show sig nificant correlation with advanced stages of the tumor, resistance to chemother apy and poor prognosis (51) . In another study involving a highly metastatic osteosarcoma cell line, the expression of tenascinC was found to be significantly downregulated (64), although Tanaka et al. (65) had suggested that tenascinC assists in osteosarcoma cell migration and therefore promotes metastasis.
Proteomics investigations, on the other hand, have unearthed potential biomarkers that appear more useful for diagnosis of osteosarcoma ( Table 1) . The majority of the proteomic studies had used 2DE-and 2DDIGE-based approaches (2,66-70), whereas only two groups of researchers had used SELDITOF MS (71) (72) (73) . In a study by Li et al. (71) , plasma levels of SAA was shown to be significantly elevated in pediatric osteosarcoma patients when This is followed by biomarkers for Ewing sarcoma and chondrosarcoma.
Most of the genomics biomarkers pro posed are of the prognostic and predic tive types, and a number of studies have listed a series of multigene classifiers or signatures to correctly classify or identify various types of bone cancer, as opposed to single protein markers derived from proteomics approaches. Focus was also toward discovery of miRNA biomarkers. In this case, almost all analyses were on tissues, with the sole exception of a study by Yuan et al. (51) , which had used serum samples in the search for a potential miRNA marker for human osteosarcoma. Compared to tissue studies, substantial amounts of sera were used to isolate suf ficient miRNA for the study.
On the other hand, the majority of biomarkers uncovered by proteomics are of the diagnostic type. The most common proteomics platforms used in biomarker research of bone tumor were 2DE and 2DDIGE. Recently, gelfree platforms such as SELDITOF MS and LCMS have also been popular among proteomics re searchers, mainly due to the requirement of small amounts of samples and the possibility of quantification analysis. Gel free platforms offer additional options for automations and are known to be less laborious compared with 2DE.
Potential biomarkers for Osteosarcoma
Osteosarcoma, also called osteogenic sarcoma, is the most common type of primary bone cancer affecting children and adolescents (52) . This tumor arises from mesenchymal cells and is charac terized by osteoblastic differentiation of the neoplastic cells. The precise etiology of osteosarcoma is essentially unknown. Several reports, which were published as early as 1972, had already suggested that viruses such as human osteosarcoma virus (53) and Moloney murine sarcoma virus (54,55) can induce osteosarcoma. Other possible causes or initiating factors of osteosarcoma include chemical agents and radiation (56) . In 2006, Bassin and co workers reported an association between myeloma and osteosarcoma (85) . It has agespecific incidence rates, where it usually develops in adults up to the age of 75 years. Chondrosarcoma affects the long bone of the extremities, pelvis and ribs, manifested by local swelling and/or pain. The causes of this tumor remain unknown, but prognosis is good for lowgrade volume of tumor. IDH1/2 mutations can be used to distinguish chondrosarcoma from chondroblastic osteosarcoma (Table 3) , where both diseases usually exhibit similar patho logic features (86) . Strong positive results of the mutation for the genes that encode for metabolic enzymes isocitrate dehydrogenase (IDH)1 and 2 were observed from patients with chondrosarcoma, whereas the lack of IDH1 or IDH2 mutations was observed in chondroblastic osteosarcoma cases. The differentiation between these two diseases is important to determine the appropriate course of action in managing the patients, since chondro sarcoma usually can be treated just by surgery, whereas chondroblastic osteo sarcoma requires surgery as well as chemotherapy. To date, there had been no reports of any proteomics studies on biomarkers for chondrosarcoma.
Potential biomarkers for Giant Cell Tumor (GCT)
Although classified as benign, GCT, also known as osteoclastoma, is locally aggressive and can recur in up to 50% of the cases (87) . It is crucial to find bio markers for this disease, since 5% of patients with aggressive GCT (stage III) may face a possibility for the tumor to metastasize to the lung, and in 1-3% of the patients, spontaneous transformation to highgrade malignancy can happen (87, 88) . GCT is rather uncommon and generally affects patients over the age of 20 years (89) . The tumor lesion is characterized by having numerous multinucleated giant cells (90) . This neoplasm is also composed of sheets of neoplastic ovoid mononuclear cells inter spersed with uniformly distributed large, osteoclastlike giant cells. Curettage is Despite being less frequent, there were quite a number of studies per formed on Ewing sarcoma in relation to the search for biomarkers (Table 2 ). In 2012, Yu et al. (80) proposed circu lating cellfree mitochondrial DNA (ccf mtDNA) for application as diag nostic and/or prognostic biomarker for Ewing sarcoma. Serum ccf mtDNA were found to be reduced in the pa tients and were deduced to be associ ated with tumor metastasis (80) . Other genomics studies proposed CXCR4 and CXCR7 genes, miR34a, cadherin-11 and MTA1 that can be used as prognostic indicators for Ewing sarcoma (81) (82) (83) . The CXCR4 and CXCR7 genes, both of which encode for chemokine receptors, can serve as predictors of poor patient survival, whereas the CXCR4 gene itself is correlated with the metastasis of Ewing sarcoma (81) . Patients with Ewing sarcoma who had very low expression of mIR34a, a miRNA that is regulated by tumor protein p53 sig naling, had a very high risk of cancer progression and recurrence within 2 years (82) . When the expression of miRNA34a was enforced, prolifera tion of the cancer cells were found to be reduced, and the sensitivity to the chemotherapy drugs, doxorubicin and vincristine, increased (82) .
To date, only one proteomics study, which suggested nucleophosmin as a po tential prognostic marker (84), has been reported for Ewing sarcoma. By using 2DDIGE as the main platform, the ex pression of nucleophosmin was found to be correlated with poor prognosis of the patients. The functional role of nucleop hosmin in the etiology of Ewing sarcoma is still unclear, but it has been linked to a few proteins, including p53, the mutation of which is associated with poor progno sis of Ewing sarcoma cases (82, 84) .
Potential biomarkers for Chondrosarcoma
Chondrosarcoma is a malignant tumor with pure hyaline cartilage dif ferentiation and the third most common primary malignancy of bone, after SAA, peroxiredoxin 2 (PRDX2) and transthyretin (TTR) have also been independently suggested for use as predictive protein biomarkers in eval uating the efficacy of treatment of pa tients with osteosarcoma (2,69,73). Jin et al. (2) , in a study comparing the SAA expression in patients before and after chemotherapy, found that the level of this protein is significantly lower after the treatment, as well after surgery. Conversely, Li et al. (73) reported that SAA was higher in good responders of postchemotherapy treatment. Aside from diagnostic and predictive uses, SAA may also serve as a prognostic bio marker, since its expression was found to be significantly increased in relapsed osteosarcoma patients (2) . PDRX2 is an important protein in the antioxidant defense mechanism and redox signaling process (77) . The expression of PDRX2 is positively correlated with poor re sponse to chemotherapy, but the role of this protein in this reaction is still vague (69) . The expression of another protein, TTR, was also significantly lower in good responders compared with poor responders to chemother apy. TTR is involved in thyroxine and retinol binding protein transportation and reacts to inflammation process. Yet, its downregulation was also observed in ovarian cancer, suggesting the regula tion of this protein is not merely because of inflammation, but is due to the pres ence of the tumor as well (73) .
Potential biomarkers for Ewing Sarcoma
Ewing sarcoma is an extremely ma lignant tumor that arises within the marrow cavity of bone. This type of bone cancer usually affects adolescents from 10 to 15 years of age, and it can dissem inate to other bones and to the lung. The etiology is still unknown but Ewing sarcoma has been hypothesized to be as sociated with cytomegalovirus, through in utero viral infection during pregnancy (78) . There is also a close relationship suggested between Ewing sarcoma and peripheral neural tumors (79) . ample, miRNA is stable in formalinfixed tissue and blood (100). However, the dis covery of genomics biomarkers usually requires invasive procedures, since a fresh tissue specimen from a primary tumor is deemed the most suitable start ing material. In this context, proteomics is a better choice for the discovery of bio markers because it can use various types of bodily fluid samples, which can be obtained in less invasive ways.
A single gene can code for multi ple proteins and hence increases their diversity. As most proteins undergo posttranslational modifications, these modifications also result in increased complexity of the proteome. The in formation of the physiologic changes mediated by these posttranslational modifications will not be available at the nucleic acid level, making proteins more dynamic and reflective of the cellular physiology compared with DNA or RNA (101) . The structure and availability of the finalized protein decisively deter mine the cell behavior and, therefore, highthroughput screening for changes in protein expression is more suitable for discovery of prognostic or predictive bio markers (102) . However, due to the com plexity of proteins and posttranslational processing, their analysis often proves to be a daunting task.
The technological advances in small molecule separation and identification, derived especially from proteomics, open the possibility for metabolites to be studied. Metabolomics, a more recent scientific field compared with proteomics and genomics, is defined as "the system atic study of smallmolecule metabolites and their changes in biological samples due to physiological stimuli or genetic modification" (103) . The most common methods used to study metabolites (both separation and identification) in biological samples are gas chromatography, capil lary electrophoresis, highperformance liquid chromatography, ultraperfor mance liquid chromatography, MS and nuclear magnetic resonance (104) . Because metabolites are related to functional phe notypes expressed in cells, tissues and Collection, preparation and analysis of samples for genomics assays have less stringent requirements than for proteomic assays. Genomics assays can use poly merase chain reaction (PCR) for sample amplification, so analyses can still be car ried out even though the amount of sam ple is limited. Proteomics does not have any amplification method analogous to PCR (97) . Most of proteomics assays re quire enrichment or purifications steps, whereas in the genomics work flow, these steps are often unnecessary (95) . How ever, gene expression techniques such as RTPCR and Northern blot are not suit able for highthroughput study, while serial analysis of gene expression (SAGE) and DNA microarray are laborious and costly (96) .
advantages and Disadvantages of biomarkers Discovered by Genomics and Proteomics approaches
There are many advantages and dis advantages of biomarkers that should be taken into consideration before being implemented in any clinical setting. Most biomarker studies strived to elim inate differential biases, and the usage of a biomarker is definitely less biased compared with questionnaires (98) . In addition, the mechanisms of disease are usually investigated and, therefore, the proposed biomarker is generally reli able when their validity is ascertained (98) . The disadvantages include timing of sample collection (which is a critical point), expensive cost of analysis, the storage of the samples, errors that might be introduced in the laboratory, the dif ficulty in establishing normal range and also ethical responsibility (98) .
The deregulation of collaborated genes (since genes normally do not function as a single unit) in a series of overlapping and interrelated networks is known to be a classic hallmark of cancer (99) . Unlike proteins, genomics informa tion carried by the DNA in an organism is stable over the entire lifetime to create and regulate proteins necessary for the cell structure and function. RNA is also stable in various types of samples, for ex the most common medical intervention if the tumor is not too aggressive (91) .
Strong expression of the TP73L gene, which encodes for p63, was exhibited by the neoplastic stromal cells of GCT tis sue, suggesting the use of this gene and p63 as diagnostic biomarkers for this dis ease (92) ( Table 4 ). In contrast to p53, the exact role of p63 in oncogenesis and spe cifically in GCT is unclear. Nevertheless, Melino (93), described p63 as a suppres sor of metastasis formation by decreasing the cell mobility and invasion. Highly aggressive tumors lose p63 expression, which then accelerates the tumorigenesis and metastasis (93) . Therefore, the value of p63 as a differential diagnostic bio marker is higher in tumors with benign properties such as GCT (93) . In addition, Conti et al. (94) , using 2DE, suggested glutathione peroxidase 1 (GPX1), thi oredoxin peroxidase (PRX), allograft inflammatory factor 1 (AIF1), ubiquitin E2N (UBE2N) and heat shock protein 27 (HSP27) as potential biomarkers in pre dicting the aggressive behavior of GCT to local recurrences or to metastasis (94) ( Table 4) . These proteins are involved in various functions involving tumorigen esis such as oxidative stress, apoptosis, angiogenesis, cell proliferation and drug resistance (94) .
GEnOMICS VErSUS PrOTEOMICS advantages and Disadvantages of Proteomics and Genomics assays
Proteomics assays have several advan tages over genomicsbased assays. Pro teomics enable the researcher to directly examine the molecular machinery of cell physiology, which include expression of the protein itself, variations of sequences and isoforms, posttranslational modifi cations and proteinprotein complex interaction (95) . Yet, proteomics profiling techniques have some practical limita tion, for example, 2DE is labor intensive, and the handling of highend equipment such as LCMS/MS and SELDITOF MS definitely requires special training for the users (96).
Several solutions have been pro posed to address these shortcomings in an attempt to bring the biomarkers to become clinically useful. Diaman dis (115) emphasized the need for biomarker scientists to possess the required analytical and clinical creden tials other than experiences from the qualitative field of science to success fully convey the biomarker's benefit to the patients. A standard stratagem that outlines the various phases of biomarker studies, from the discovery strategies through the validation phases toward the intended use of the discov ered biomarkers, has to be implemented (116, 117) . Finally, a well validated biomarker, which may not be useful enough for clinical practice when used solely, may be combined with other clinical or biomarker data to identify the clinical scenarios (113, 118) .
COnCLUSIOn
Numerous putative biomarkers have been proposed over the years for bone tumors, which involved multiple re search platforms. These biomarkers, mainly for osteosarcoma, Ewing sar coma, chondrosarcoma and GCT, have prognostic, diagnostic and/or predictive values, and the majority of which were discovered by genomics and proteomics approaches. Despite this, the devastating presentday reality is that none of these tumor biomarkers have managed to get into the clinical utility.
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freeze and thaw cycles, storage condi tions, association with menstrual cycle, and diet and drug use, and not from presence of the cancer itself (109) .
Variation of results is also known to exist from independent genomics inves tigations to find new prognostic gene signatures (110) . The possible causes identified were poor study design, lack of a standard technology platform, nonstan dardized sample collection procedures, difference in statistical method applied in each study and differences in input cohorts for the study (110) . Such incoher ence is also present in the field of pro teomics. For example, in 2005, Baggerly et al. (111) raised controversy by questioning the reproducibility of a report by Petricoin et al. (34) . In the study, the SELDITOF MS platform was used to correctly classify and discriminate all the ovarian cancer cases from nonmalignant disorders. Based on the data that were made publicly available by Petricoin's group in a website in 2004, Baggerly et al. (112) reexamined the reproducibility of the work and con cluded that "much of the structure uncov ered in these experiments could be due to artefacts of sample processing, not to the underlying biology of cancer."
The question of why protein biomark ers for cancer usually failed to reach the clinic has been attributed to three main reasons (113) . First is fraudulent publications, which are actually quite rare (114) . Second is the inability of the biomarkers to meet the demands by clin ics due to low specificity, low sensitivity and low prognostic/predictive value, despite being successfully validated. To obtain approval from the FDA, clinical trials have to be conducted for the pro posed biomarkers, but the expensive cost and various organizations that need to be involved sometimes impede decisions to further bring the potential biomarker into the clinics. Third is false discovery, where some biomarkers that initially look promising fail to make it through because of preanalytical, ana lytical, postanalytical and bioinformatics shortcomings at either discovery or the validation phase (113) . organisms, metabolite biomarkers could be a good complementary to the genom ics and proteomics biomarkers. However, metabolomics possesses one critical advan tage over the other "omics" technologies, where each metabolite has the same basic chemical structure, regardless of the type of the organism, and therefore readily transferable from one species to another (105, 106) . The other favorable features of metabolomics for biomarker discovery have been elaborated elsewhere (106) . Recently, a group of researchers have des cribed a possible mean to forecast risk of breast cancer (up to 5 years) among women using plasma metabolomics and biocon tour, with higher sensitivity and speci ficity than mammography (107) . This metabolic forecasting of cancer may provide new insight in cancer etiology, besides being useful for early detection of the cancer (107) .
ChaLLEnGES In bIOMarKEr DISCOVErY anD IMPLEMEnTaTIOn
Despite numerous reports of potential biomarkers uncovered from genomics and proteomics studies, the fact remains that these markers are still far from making their way closer to the patients. In the case of bone tumor, none of the potential biomarkers has currently been applied in clinical use. Genomics and proteomics technologies have produced close to 100,000 articles on biomarkers combined (PubMed search on April 15, 2015, keywords "proteomics biomarker" and "genomics biomarker"), but out of these, less than 100 managed to be val idated for clinical use (108) . In clinical practice, clinicians usually depend on numeric cutoff points when evaluating tumor markers. However, research in biomarkers usually proposed a set of genomics or proteomics signature, or fin gerprint patterns, instead of a single bio marker, in distinguishing disease from normal conditions. The downside of this is that such patterns may at times be due to factors presented during collection of samples, such as the analysis of lipemic and hemolyzed samples, varying icteric index in the case of hyperbilirubinemia,
